AzTrials
AzTrials

Adults Patients, With Fecal Carriage of Multi-Drug Resistant Enterobacterales (MDR-E)HOMENCT05798364

Household Transmission Dynamics of Multidrug Resistant Enterobacterales

An observational study of Adults Patients, With Fecal Carriage of Multi-Drug Resistant Enterobacterales (MDR-E), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

Unknown status

Status not confirmed. The sponsor has not verified this record for over two years, so it may be out of date.

Official record
Search all trials

Trial summary

The HOME study will prospectively follow a cohort of Multi-Drug Resistant Enterobacterales (MDR-E) carriers after hospital discharge, and their related household members over a 3-month period. Read more about this study

Who is it for?
Any ageHealthy volunteers can take part
How many people
507 participants
Where
1 siteFrance
Study dates
19 May 2023to Sep 2026
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages Any age
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Study population: Adults MDR-E carriers (index patients) and their related household members (children, pregnant and breastfeeding women included)

Who may be able to join

  • Index patients
  • adults (≥ 18 years)
  • hospitalized in participating hospitals
  • positive for MDR-E fecal carriage on routine screening during hospital stay
  • with no documented MDR-E fecal carriage in the 12 months preceding current hospitalization
  • regularly living with at least two additional household members who expressed their non-opposition to participate.
Show all 9Show fewer
  • planning to live in Ile de France for the next three months Household members
  • adults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion, and who expressed their non-opposition to participate.
  • planning to live in Ile de France for the next three months

Who cannot join

  • Lack of non-opposition to participate and to use clinical data
  • Subject under legal protection (guardianship)
  • Subject deprived of liberty under judicial constraint
  • Subject undergoing psychiatric care
  • Lack of affiliation to a social security scheme Secondary exclusion criteria
  • Index member negative for MDR-E fecal carriage either before discharge (D-7 to D-2) or on day of discharge (D0)."

Trial locations and contacts

1 site in 1 country.

Kernéis Solen, MD, PhD contact

+33 1 40 25 61 99

solen.kerneis@aphp.fr

Armand-Lefevre Laurence, Pharm. D., PhD. contact

+33 1 40 25 85 00

laurence.armand@aphp.fr

France1 site, 1 recruiting
  • Bichat Hospital

    Paris, Île-de-France Region, 75018

    Solen Kernéis, MD - PhD, 33140256199, solen.kerneis@aphp.fr

    Claire Durand, MD, 33686016726, durand.c@chu-nice.fr

    Recruiting

Other trials in France

About this study

The HOME study will prospectively follow a cohort of Multi-Drug Resistant Enterobacterales (MDR-E) carriers after hospital discharge, and their related household members over a 3-month period. The main objective is to estimate the rate of confirmed transmissions of MDR-E from the index cases to related household members, and identify predictors associated with transmission. Transmission will be confirmed by comparing genomic analysis of the MDR-E strains isolated both in the index patient and his/her household members, based on the number of Single nucleotide polymorphisms (SNPs) differences between nearby genomes by Variant Calling. Multifactorial processes involved in MDR-E transmission in households will be explored with stochastic individual-based modelling. The parameterized model will be used to simulate and assess different strategies of control of MDR-E emergence and transmission to households. The impact of modifying patterns of human-contacts, promote hygiene and control barriers (decontamination of objects or surfaces, variations in antibiotic use, reinforcement of hand hygiene) will be assessed.

Read the detailed description

Multi-Drug Resistant Enterobacterales (MDR-E), i.e. Extended-Spectrum Beta-Lactamase producing Enterobacterales (ESBL-E) and Carbapenemase-Producing Enterobacterales (CPE) are spreading worldwide. Although initially considered a healthcare-associated problem, reports of ESBL-E carriage and infections in individuals without any previous exposure to health care raise concerns on their alarming dissemination in the community. Very few reports investigated the dynamics of transmission of MDR-E from carriers to household members. Risk factors of acquisition (related to the strain, household habits, travel, occupational activities…) were poorly assessed.

Quantifying and understanding the mechanisms of household transmission is of major importance to elaborate control strategies specifically designed to the community.

The main objective is to estimate the rate of confirmed transmissions of MDR-E from an index case to related household members.

The primary endpoint is defined by the secondary attack rate (SAR) for confirmed transmissions, i.e. the proportion of confirmed (based on genetic analysis of strains) acquisitions of MDR-E in all household members over the study period (three months).

Screening of eligible patients will rely on an automated daily request of all MDR-E positive samples that is already implemented in the participating centers.

Information on the study will be given to eligible patients, those who meet eligibility criteria and willing to participate will be asked to ive non-opposition.

Seven days before hospital discharge, index patients who consent to participate will provide a fecal sample to be screened for MDR-E carriage. If the patient is still positive at discharge for MDR-E fecal carriage, he/she will be included in the cohort (=index case). His/her household members (=HH members) will then be invited to participate and included after agreement.

After inclusion, index cases and household members will be prospectively followed-up for 3 months (+/-7 days), and asked to provide self-collected stool samples and questionnaires on day7, day15, day21, day30, month2 and month3.

Self-collected stool samples will be mailed to the reference microbiology laboratory (Bichat) with self-filled questionnaires.

In addition, in the context of the ancillary study:

To obtain accurate data on interactions between household members, Ultra Wide Band (UWB) systems will be used. During 4 days, index cases and household members will wear a small wireless sensor that records continuously the identity of other sensors that are in close proximity. For each household, recording will be performed on 2 week days and 2 week-end days (Saturday and Sunday).

Proportion of transmissions in all household members over the study period (SAR) and 95% confidence intervals will be calculated at the end of follow-up for both probable and confirmed transmissions and described according to household size and index-case population type. Kaplan Meier survival analysis will be used to estimate the median time to (first) acquisition among household members and a Cox shared frailty-model to study variables associated with acquisition index-case and household members' potential exposures, household's characteristics, MDR-E abundance in index case-patients, intestinal microbiota diversity and composition). Additionally, a stochastic individual based model to capture the multifactorial processes involved in MDR-E transmission will developed. Several models of increasing complexity will be built in order to compare their likelihood given the acquisitions observed over time in the different households. The model will be integrated in an inference framework to analyse the data and estimate model parameters (eg transmission rates for the different routes). The inference techniques will involve bayesian statistics, probably Markov Chain Monte Carlo with data augmentation. The different models will be compared based on specific criterion, such as the Deviance Information Criterion (DIC). The parameterized model selected in the preceding step will be used to simulate and assess different strategies of control of MDR-E emergence and transmission to households.

Keywords
Multi-Drug Resistant Enterobacterales ; ; ; ;, Extended-Spectrum Beta-Lactamase producing Enterobacterales, Carbapenemase-Producing Enterobacterales, Transmission, Community, households, Mathematical modelling, microbiota, Whole genome sequencing

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Study groups in NCT05798364
Study groupRoleWhat they receive
Index patientsAdults MDR-E carriers.
Household membersAdults or children living in the same household as the index case (i.e. sharing the same kitchen and/or bathroom and/or toilets) during the 3 months following inclusion

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Secondary attack rate (SAR) for confirmed transmissions, i.e. the proportion of confirmed acquisitions of MDR-E (based on genetic analysis of strains) in all household members over the study period

    Measured: 3 months

Secondary outcomes (10)
  1. SAR for possible transmissions, i.e. the proportion of possible (based on phenotypic analysis of strains) acquisitions of MDR-E in all household members over the study period

    Measured: 3 months

  2. Hazard ratios of epidemiological and microbiological factors associated with confirmed transmission

    Measured: 3 months

  3. Median time to decolonization in MDR-E carriers (index or household members)

    Measured: 3 months

  4. Hazard ratios of epidemiological and microbiological factors associated with decolonization

    Measured: 3 months

  5. Diversity indices of the microbiota (Shannon diversity index) in pairs index/household member with or without confirmed transmission

    Measured: 3 months

  6. Number of interactions between index patients and household participants

    Measured: 4 days

  7. Duration of interactions between index and household participants

    Measured: 4 days

  8. Number of observed Operational Taxonomic Units in pairs index/household member with or without confirmed transmission

    Measured: 3 months

  9. Bray-Curtis unweighted UniFrac distance in pairs index/household member with or without confirmed transmission

    Measured: 3 months

  10. Bray-Curtis dissimilarity in pairs index/household member with or without confirmed transmission

    Measured: 3 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted4 Apr 2023
  2. Study start19 May 2023
  3. Primary completionMay 2026 (estimated)
  4. Study completionSep 2026 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
507 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT05798364
Sponsor's protocol ID
APHP220479
Acronym
HOME
Status last verified
Jun 2024
First submitted
6 Jan 2023
Last updated
4 Jun 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No

Questions about this trial

What is this clinical trial studying?

An observational study of Adults Patients, With Fecal Carriage of Multi-Drug Resistant Enterobacterales (MDR-E), run by Assistance Publique - Hôpitaux de Paris at 1 site in France.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 9 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: status not confirmed, as of the sponsor's last update on 4 Jun 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in France. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

Results are not available in the source record.

How can a doctor refer a patient or contact the research team?

Contact Kernéis Solen, MD, PhD (+33 1 40 25 61 99, solen.kerneis@aphp.fr), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Secondary attack rate (SAR) for confirmed transmissions, i.e. the proportion of confirmed acquisitions of MDR-E (based on genetic analysis of strains) in all household members over the study period (time frame: 3 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Jun 2024.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in